Literature DB >> 33155281

Immunotherapeutic strategies in breast cancer: A clinical update.

Jennifer Q Zhang1, George Plitas1,2.   

Abstract

Immunotherapy has been incorporated into the standard of care for a wide range of malignancies. The study of tumor-infiltrating lymphocytes has emphasized the importance of the host antitumor immune response in the natural history of breast cancer. Recent clinical trials have used immunotherapeutic approaches to augment this response and improve outcomes for patients with breast cancer. Here, we review several current clinical trial data that indicate checkpoint blockade may mediate clinically significant responses.
© 2020 Wiley Periodicals LLC.

Entities:  

Keywords:  checkpoint blockade; immunotherapy; outcomes

Mesh：

Substances：

Year:  2020        PMID： 33155281      PMCID： PMC7889634          DOI： 10.1002/jso.26287

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN： 0022-4790            Impact factor:   3.454


  48 in total

1.  Cancer statistics, 2019.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2019-01-08       Impact factor: 508.702

2.  Association Between Genomic Metrics and Immune Infiltration in Triple-Negative Breast Cancer.

Authors:  Thomas Karn; Tingting Jiang; Christos Hatzis; Nicole Sänger; Ahmed El-Balat; Achim Rody; Uwe Holtrich; Sven Becker; Giampaolo Bianchini; Lajos Pusztai
Journal:  JAMA Oncol       Date:  2017-12-01       Impact factor: 31.777

3.  Differences in Breast Cancer Survival by Molecular Subtypes in the United States.

Authors:  Nadia Howlader; Kathleen A Cronin; Allison W Kurian; Rebecca Andridge
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-03-28       Impact factor: 4.254

4.  Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.

Authors:  Carsten Denkert; Gunter von Minckwitz; Silvia Darb-Esfahani; Bianca Lederer; Barbara I Heppner; Karsten E Weber; Jan Budczies; Jens Huober; Frederick Klauschen; Jenny Furlanetto; Wolfgang D Schmitt; Jens-Uwe Blohmer; Thomas Karn; Berit M Pfitzner; Sherko Kümmel; Knut Engels; Andreas Schneeweiss; Arndt Hartmann; Aurelia Noske; Peter A Fasching; Christian Jackisch; Marion van Mackelenbergh; Peter Sinn; Christian Schem; Claus Hanusch; Michael Untch; Sibylle Loibl
Journal:  Lancet Oncol       Date:  2017-12-07       Impact factor: 41.316

5.  Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis.

Authors:  Sandhya Manohar; Panagiotis Kompotiatis; Charat Thongprayoon; Wisit Cheungpasitporn; Joerg Herrmann; Sandra M Herrmann
Journal:  Nephrol Dial Transplant       Date:  2019-01-01       Impact factor: 5.992

Review 6.  PD-1 and its ligands in tolerance and immunity.

Authors:  Mary E Keir; Manish J Butte; Gordon J Freeman; Arlene H Sharpe
Journal:  Annu Rev Immunol       Date:  2008       Impact factor: 28.527

Review 7.  Clinical relevance of host immunity in breast cancer: from TILs to the clinic.

Authors:  Peter Savas; Roberto Salgado; Carsten Denkert; Christos Sotiriou; Phillip K Darcy; Mark J Smyth; Sherene Loi
Journal:  Nat Rev Clin Oncol       Date:  2015-12-15       Impact factor: 66.675

8.  Pembrolizumab for Early Triple-Negative Breast Cancer.

Authors:  Peter Schmid; Javier Cortes; Lajos Pusztai; Heather McArthur; Sherko Kümmel; Jonas Bergh; Carsten Denkert; Yeon Hee Park; Rina Hui; Nadia Harbeck; Masato Takahashi; Theodoros Foukakis; Peter A Fasching; Fatima Cardoso; Michael Untch; Liyi Jia; Vassiliki Karantza; Jing Zhao; Gursel Aktan; Rebecca Dent; Joyce O'Shaughnessy
Journal:  N Engl J Med       Date:  2020-02-27       Impact factor: 176.079

9.  Programmed death-ligand 1 (PD-L1) expression in tumour cell and tumour infiltrating lymphocytes of HER2-positive breast cancer and its prognostic value.

Authors:  Ahrong Kim; So Jeong Lee; Young Keum Kim; Won Young Park; Do Youn Park; Jee Yeon Kim; Chang Hun Lee; Gyungyub Gong; Gi Yeong Huh; Kyung Un Choi
Journal:  Sci Rep       Date:  2017-09-15       Impact factor: 4.379

10.  Pan-cancer analysis of intratumor heterogeneity as a prognostic determinant of survival.

Authors:  Luc G T Morris; Nadeem Riaz; Alexis Desrichard; Yasin Şenbabaoğlu; A Ari Hakimi; Vladimir Makarov; Jorge S Reis-Filho; Timothy A Chan
Journal:  Oncotarget       Date:  2016-03-01
View more
  3 in total

1.  Exercise Training Improves Tumor Control by Increasing CD8+ T-cell Infiltration via CXCR3 Signaling and Sensitizes Breast Cancer to Immune Checkpoint Blockade.

Authors:  Igor L Gomes-Santos; Zohreh Amoozgar; Ashwin S Kumar; William W Ho; Kangsan Roh; Nilesh P Talele; Hannah Curtis; Kosuke Kawaguchi; Rakesh K Jain; Dai Fukumura
Journal:  Cancer Immunol Res       Date:  2021-04-10       Impact factor: 11.151

2.  A Tumor Suppressor Gene-Based Prognostic Classifier Predicts Prognosis, Tumor Immune Infiltration, and Small Molecule Compounds in Breast Cancer.

Authors:  Suxiao Jiang; Xiangjing Bu; Desheng Tang; Changsheng Yan; Yan Huang; Kun Fang
Journal:  Front Genet       Date:  2022-02-03       Impact factor: 4.599

3.  Differential Gene Analysis of Trastuzumab in Breast Cancer Based on Network Pharmacology and Medical Images.

Authors:  Yuan Lu; Juan Bi; Fei Li; Gang Wang; Junjie Zhu; Jiqing Jin; Yueyun Liu
Journal:  Front Physiol       Date:  2022-07-08       Impact factor: 4.755
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.